Table of Contents

1. Introduction
    1.1 Market Definition & Scope
    1.2 Research Assumptions & Abbreviations
    1.3 Research Methodology

2. Executive Summary
    2.1 Market Snapshot
    2.2 Market Absolute $ Opportunity Assessment & Y-o-Y Analysis, 2022 – 2035
    2.3 Market Size & Forecast, By Segmentation, 2022 – 2035
     2.3.1 Market Size By Type
     2.3.2 Market Size By Application
     2.3.3 Market Size By End User
    2.4 Market Share & Bps Analysis By Region, 2025
    2.5 Industry Growth Scenarios – Conservative, Likely & Optimistic
    2.6 Industry CxO's Perspective

3. Market Overview
    3.1 Market Dynamics
     3.1.1 Drivers
     3.1.2 Restraints
     3.1.3 Opportunities
     3.1.4 Key Market Trends
    3.2 Industry PESTLE Analysis
    3.3 Key Industry Forces (Porter's) Impacting Market Growth
    3.4 Industry Supply Chain Analysis
     3.4.1 mRNA Technology Developers & Platform Providers
     3.4.2 Manufacturing & Formulation Partners
     3.4.3 Healthcare Providers, Hospitals, Research Organizations (End-Users)
     3.4.4 Patients & Clinical Trial Participants (End Consumers)
    3.5 Industry Life Cycle Assessment
    3.6 Parent Market Overview (Biotechnology & Genetic Medicine)
    3.7 Market Risk Assessment

4. Statistical Insights & Trends Reporting
    4.1 Clinical Development & Pipeline Metrics
     4.1.1 Overview
     4.1.2 Global mRNA Therapeutic Candidates in Clinical Trials (Phase I-III)
     4.1.3 Average Development Timeline from IND to Approval
     4.1.4 Clinical Success Rates by Therapeutic Application
     4.1.5 Regulatory Approval Trends & Breakthrough Designations

 4.2 Manufacturing & Technology Adoption Metrics
  4.2.1 Overview
  4.2.2 Global mRNA Manufacturing Capacity & Expansion Investments
  4.2.3 Lipid Nanoparticle Technology Adoption Rates
  4.2.4 Thermostability Enhancement & Cold Chain Optimization Trends
  4.2.5 Contract Development & Manufacturing Organization (CDMO) Utilization

 4.3 Investment & Funding Metrics
  4.3.1 Overview
  4.3.2 Venture Capital Investment in mRNA Biotechnology Companies
  4.3.3 Strategic Partnerships & Licensing Agreement Values
  4.3.4 Government Funding for mRNA Research & Infrastructure
  4.3.5 M&A Activity & Technology Acquisition Trends

 4.4 Patient Access & Market Penetration Metrics
  4.4.1 Overview
  4.4.2 Global Vaccination Coverage & mRNA Vaccine Distribution
  4.4.3 Cancer Immunotherapy Patient Enrollment Rates
  4.4.4 Rare Disease Treatment Accessibility & Orphan Drug Approvals
  4.4.5 Healthcare Provider Adoption & Prescribing Patterns

5. mRNA Therapeutics Market Segmental Analysis & Forecast, By Type, 2022 – 2035, Value (USD Billion)
    5.1 Introduction
    5.2 Prophylactic Vaccines
     5.2.1 Key Trends
     5.2.2 Market Size & Forecast, 2022 – 2035
    5.3 Therapeutic Vaccines
    5.4 Therapeutic Drugs

6. mRNA Therapeutics Market Segmental Analysis & Forecast, By Application, 2022 – 2035, Value (USD Billion)
    6.1 Introduction
    6.2 Rare Genetic Disease
     6.2.1 Key Trends
     6.2.2 Market Size & Forecast, 2022 – 2035
    6.3 Respiratory Disease
    6.4 Infectious Disease

7. mRNA Therapeutics Market Segmental Analysis & Forecast, By End User, 2022 – 2035, Value (USD Billion)
    7.1 Introduction
    7.2 Hospitals and Clinics
     7.2.1 Key Trends
     7.2.2 Market Size & Forecast, 2022 – 2035
    7.3 Research Organizations

8. mRNA Therapeutics Market Segmental Analysis & Forecast By Region, 2022 – 2035, Value (USD Billion)
    8.1 Introduction
    8.2 North America
     8.2.1 Key Trends
     8.2.2 mRNA Therapeutics Market Size & Forecast, By Type, 2022 – 2035
     8.2.3 mRNA Therapeutics Market Size & Forecast, By Application, 2022 – 2035
     8.2.4 mRNA Therapeutics Market Size & Forecast, By End User, 2022 – 2035
     8.2.5 mRNA Therapeutics Market Size & Forecast, By Country, 2022 – 2035
      8.2.5.1 USA
      8.2.5.2 Canada

 8.3 Europe
  8.3.1 Key Trends
  8.3.2 mRNA Therapeutics Market Size & Forecast, By Type, 2022 – 2035
  8.3.3 mRNA Therapeutics Market Size & Forecast, By Application, 2022 – 2035
  8.3.4 mRNA Therapeutics Market Size & Forecast, By End User, 2022 – 2035
  8.3.5 mRNA Therapeutics Market Size & Forecast, By Country, 2022 – 2035
   8.3.5.1 Germany
   8.3.5.2 UK
   8.3.5.3 France
   8.3.5.4 Italy
   8.3.5.5 Spain
   8.3.5.6 Russia
   8.3.5.7 Poland
   8.3.5.8 Rest of Europe

 8.4 Asia-Pacific
  8.4.1 Key Trends
  8.4.2 mRNA Therapeutics Market Size & Forecast, By Type, 2022 – 2035
  8.4.3 mRNA Therapeutics Market Size & Forecast, By Application, 2022 – 2035
  8.4.4 mRNA Therapeutics Market Size & Forecast, By End User, 2022 – 2035
  8.4.5 mRNA Therapeutics Market Size & Forecast, By Country, 2022 – 2035
   8.4.5.1 China
   8.4.5.2 India
   8.4.5.3 Japan
   8.4.5.4 South Korea
   8.4.5.5 Australia
   8.4.5.6 ASEAN Countries
   8.4.5.7 Rest of Asia-Pacific

 8.5 Latin America
  8.5.1 Key Trends
  8.5.2 mRNA Therapeutics Market Size & Forecast, By Type, 2022 – 2035
  8.5.3 mRNA Therapeutics Market Size & Forecast, By Application, 2022 – 2035
  8.5.4 mRNA Therapeutics Market Size & Forecast, By End User, 2022 – 2035
  8.5.5 mRNA Therapeutics Market Size & Forecast, By Country, 2022 – 2035
   8.5.5.1 Brazil
   8.5.5.2 Argentina
   8.5.5.3 Mexico
   8.5.5.4 Colombia
   8.5.5.5 Rest of Latin America

 8.6 Middle East & Africa
  8.6.1 Key Trends
  8.6.2 mRNA Therapeutics Market Size & Forecast, By Type, 2022 – 2035
  8.6.3 mRNA Therapeutics Market Size & Forecast, By Application, 2022 – 2035
  8.6.4 mRNA Therapeutics Market Size & Forecast, By End User, 2022 – 2035
  8.6.5 mRNA Therapeutics Market Size & Forecast, By Country, 2022 – 2035
   8.6.5.1 UAE
   8.6.5.2 Saudi Arabia
   8.6.5.3 Qatar
   8.6.5.4 Egypt
   8.6.5.5 South Africa
   8.6.5.6 Rest of Middle East & Africa

9. Competitive Landscape
    9.1 Key Players' Positioning
    9.2 Competitive Developments
     9.2.1 Key Strategies Adopted (%), By Key Players, 2025
     9.2.2 Year-Wise Strategies & Development, 2021 – 2025
     9.2.3 Number Of Strategies Adopted By Key Players, 2025
    9.3 Market Share Analysis, 2025
    9.4 Product/Service & Application Benchmarking
     9.4.1 Product/Service Specifications & Features By Key Players
     9.4.2 Product/Service Heatmap By Key Players
     9.4.3 Application Heatmap By Key Players
    9.5 Industry Start-Up & Innovation Landscape
    9.6 Key Company Profiles
     9.6.1 Moderna, Inc.
      9.6.1.1 Company Overview & Snapshot
      9.6.1.2 Product/Service Portfolio
      9.6.1.3 Key Company Financials
      9.6.1.4 SWOT Analysis
     9.6.2 BioNTech SE
     9.6.3 Pfizer Inc.
     9.6.4 CureVac N.V.
     9.6.5 Translate Bio (Sanofi)
     9.6.6 Arcturus Therapeutics Holdings Inc.
     9.6.7 eTheRNA Immunotherapies
     9.6.8 Argos Therapeutics
     9.6.9 In-Cell-Art
     9.6.10 Ethris GmbH
     9.6.11 Acuitas Therapeutics
     9.6.12 Precision NanoSystems
     9.6.13 GlaxoSmithKline plc
     9.6.14 AstraZeneca plc
     9.6.15 Sanofi S.A.
     9.6.16 Merck & Co., Inc.
     9.6.17 Novartis AG
     9.6.18 Roche Holding AG
     9.6.19 Eli Lilly and Company
     9.6.20 Takeda Pharmaceutical Company Limited

10. Analyst Recommendations
     10.1 SNS Insider Opportunity Map
     10.2 Industry Low-Hanging Fruit Assessment
     10.3 Market Entry & Growth Strategy
     10.4 Analyst Viewpoint & Suggestions on Market Growth

11. Assumptions

12. Disclaimer

13. Appendix
     13.1 List Of Tables
     13.2 List Of Figures